Podcasts about artemisinin resistance

Drug efficacy studies are revealing the spatial distribution of mutations causing artemisinin resistance - and it all starts with a drop of blood. In this podcast, we ask: What is artemisinin resistance? What are some of the key molecular markers underpinning it? How can we overcome it? With Didier Ménard, Director of the Institute of Parasitology and Tropical Diseases at the University of Strasbourg, and a visiting researcher at the Pasteur Institute. About The Podcast The Johns Hopkins Malaria Minute is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

Drug resistance is on the rise, but genetics can help us understand what's driving it. Here, researchers identify a protein associated with resistance to artemisinin, a key malaria drug. Transcript Artemisinin-based combination therapies (ACT) are considered the most effective method to treat malaria. Yet drug resistance to them is on the rise, spreading from Southeast Asia to Africa, becoming a real problem. A genetic approach to drug resistance can help us understand the genes responsible for this. Artemisinin resistance has long been associated with mutations to a protein called Kelch13. By screening the parasite genome, researchers have identified another protein associated with resistance to the drug. Called KIC5, this protein helps maintain nuclear homeostasis – balance within the parasite's cell – as it lives in human red blood cells. When expressed, it helps the parasite overcome artemisinin stress by supporting DNA repair and other mitochondrial activity. But when it's disrupted, the parasite can't deal with this stress and becomes sensitized to the drug. Almost like flipping a switch, disrupting KIC5 makes artemisinin work again. Source Protein KIC5 is a novel regulator of artemisinin stress response in the malaria parasite Plasmodium falciparum About The Podcast The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

Episode 39 With the confirmation that malaria parasites in Rwanda have developed resistance to artemisinin — a first-line drug used to treat malaria, which kills around 400,000 people a year worldwide — public health teams in Africa are asking what this could mean for the battle against malaria. Elsewhere on the continent, malaria vaccine trials have reported success.   This week on Africa Science Focus, reporter Charles Pensulo speaks to Karen Barnes from the University of Cape Town, who leads the Worldwide Antimalarial Resistance Network's Southern Africa Regional Centre, and malaria specialist Elizabeth Juma, a medical officer with the World Health Organization.  And, in this week's Q&A segment, Wakin Octavia from Henry Henderson Institute in Malawi has a question about chemistry. Is there something you want to know about life, health or science in Africa? Send us your questions from anywhere in the world and we'll find an expert to answer them — text or voice message via WhatsApp to +254799042513.  Africa Science Focus, with Selly Amutabi. Do you have any comments, questions or feedback about our podcast episodes? Let us know at podcast@scidev.net

The Latest Malaria News, in 60 Seconds. Researchers identify a mutation to the malaria parasite which can drive resistance to artemisinin and people around the world mark World Mosquito Week. More: www.fightmalaria.uk/MalariaMinute

The Latest Malaria News, in 60 Seconds. A mechanism of resistance to artemisinin is identified and researchers find that breastfeeding could help to prevent malaria in babies. More: www.fightmalaria.uk/MalariaMinute

Dr. Sanjeev Krishna is a professor of molecular parasitology and medicine at St. George’s, University of London. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Wang and Others. A Temporizing Solution to “Artemisinin Resistance”. N Engl J Med 2019;380:2087-2089.

El programa de esta semana lo dedicamos a discutir varios temas relacionados con malaria a propósito del reporte de la Organización Mundial de la Salud correspondiente al 2017 (con datos del 2016) referente a este tema.   Referencias: WHO. World Malaria Report 2017 La malaria avanza sin frenos. Por Marielba Nunez. El Nacional. Nov 26, 2017. Polycarp Mogeni y colaboradores. Detecting Malaria Hotspots: A Comparison of Rapid Diagnostic Test, Microscopy, and Polymerase Chain Reaction. J Infect Dis. Nov 2017. Patricia Solis, Mariano Gustavo Zolis y colaboradores. Outbreak of human malaria caused by Plasmodium simium in the Atlantic Forest in Rio de Janeiro: a molecular epidemiological investigation  Lancet Glob Health 2017. A. Ashley y colaboradores. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med. 2014 Mallika Imwong y colaboradores. The spread of artemisinin-resistant Plasmodiumfalciparumin the Greater Mekongs ubregion: amolecular epidemiology observational study. Lancet Infectious Dis. May 2017 Mallika Imwong y colaboradores. Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis. Octubre 2017. WHO . Status Report on Aatemisinin and artemisinin-based combination therapy resistance. April 2017   La Frase de la Semana: La tomamos de Richard Phillips Feynman (11 de mayo de 1918 - 15 de febrero de 1988) fue un físico teórico estadounidense conocido por su trabajo en la formulación integral de ruta de la mecánica cuántica, la teoría de la electrodinámica cuántica, así como en la física de partículas. Ayudó en el desarrollo de la bomba atómica, amplió la comprensión de la electrodinámica cuántica, tradujo jeroglíficos mayas y e identifico la base del desastre del transbordador espacial Challenger. Por sus contribuciones al desarrollo de la electrodinámica cuántica, Feynman, , recibió el Premio Nobel de Física en 1965.  La frase dice asi: “La religión es la cultura de la fe; la ciencia es la cultura de la duda.”      

Dr Mehul Dhorda heads the Asia Regional Centre of the WorldWide Antimalarial Resistance Network (WWARN). Artemisinin resistance is firmly established in many parts of Southeast Asia and threatens the lives of millions of people. To improve regional intelligence and aid containment efforts, Dr Dhorda promotes the collection of high quality data on malaria drug resistance. His research aims to simplify and harmonise data, securely store results and analyse comparative or collective pooled analyses.

Dr Mehul Dhorda heads the Asia Regional Centre of the WorldWide Antimalarial Resistance Network (WWARN). Artemisinin resistance is firmly established in many parts of Southeast Asia and threatens the lives of millions of people. To improve regional intelligence and aid containment efforts, Dr Dhorda promotes the collection of high quality data on malaria drug resistance. His research aims to simplify and harmonise data, securely store results and analyse comparative or collective pooled analyses.

Dr Kesinee Chotivanich's laboratory provides facilities and resources to researchers, students, and collaborators who are interested in tropical diseases, with the aim to improve patients' care. More effective diagnosis and treatments are needed to reduce the morbidity and mortality affecting malaria patients. Researchers at the Malaria Laboratory at MORU study the pathophysiology of the disease, and test new compound drugs for anti-malarial activity. In the context of growing artemisinin resistance, this research will have a global impact.

Dr Kesinee Chotivanich's laboratory provides facilities and resources to researchers, students, and collaborators who are interested in tropical diseases, with the aim to improve patients' care. More effective diagnosis and treatments are needed to reduce the morbidity and mortality affecting malaria patients. Researchers at the Malaria Laboratory at MORU study the pathophysiology of the disease, and test new compound drugs for anti-malarial activity. In the context of growing artemisinin resistance, this research will have a global impact.

Artemisinins are very poweful tools in the treatment of malaria, and the emerging loss of their activity has the potential to create a major public health problem. MALARIA TREATMENT Dr Charlie Woodrow is based at MORU in Bangkok, Thailand, where he coordinates clinical and laboratory studies on resistance to artemisinins. Bringing together diverse datasets of clinical, in vitro and molecular data has helped better understand the emerging resistance, particularly in Myanmar.

Artemisinins are very poweful tools in the treatment of malaria, and the emerging loss of their activity has the potential to create a major public health problem. MALARIA TREATMENT Dr Charlie Woodrow is based at MORU in Bangkok, Thailand, where he coordinates clinical and laboratory studies on resistance to artemisinins. Bringing together diverse datasets of clinical, in vitro and molecular data has helped better understand the emerging resistance, particularly in Myanmar.

Artemisinins are very poweful tools in the treatment of malaria, and the emerging loss of their activity has the potential to create a major public health problem. MALARIA TREATMENT Dr Charlie Woodrow is based at MORU in Bangkok, Thailand, where he coordinates clinical and laboratory studies on resistance to artemisinins. Bringing together diverse datasets of clinical, in vitro and molecular data has helped better understand the emerging resistance, particularly in Myanmar.

Artemisinins are very poweful tools in the treatment of malaria, and the emerging loss of their activity has the potential to create a major public health problem. MALARIA TREATMENT Dr Charlie Woodrow is based at MORU in Bangkok, Thailand, where he coordinates clinical and laboratory studies on resistance to artemisinins. Bringing together diverse datasets of clinical, in vitro and molecular data has helped better understand the emerging resistance, particularly in Myanmar.

PHILADELPHIA—Research findings on gene changes enabling malaria parasites to resist anti-malarial drugs were discussed at the American Society of Tropical Medicine and Hygiene meeting in Philadelphia. This has come in the midst of worries about the slow rise in resistance to the most modern group of drugs — artemisinin combinations — in Cambodia and Thailand. Professor David Conway of the London School of Hygiene and Tropical Medicine gave Peter Goodwin some of the details.